verteporfin

(redirected from Benzoporphyrin)

verteporfin

 [ver″tĕ-por´fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathologic myopia; the agent is then activated by light of a specific wavelength in the presence of oxygen, and causes local damage to the neovascular endothelium followed by vessel occlusion; it is administered intravenously prior to irradiation of the lesion with light from a compatible laser.

ver·te·por·fin

(vĕr-tē-pōr'fin),
Photosensitizer agent used in photodynamic therapy to treat choroidal neovascularization secondary to age related macular degeneration.

verteporfin

/ver·te·por·fin/ (ver″tĕ-por´fin) a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid; used, together with appropriate laser irradiation of the lesion, in the treatment of neovascularization due to disciform macular degeneration, to presumed ocular histoplasmosis, or to pathologic myopia.

verteporfin

[ver′tĕ-por′fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathological myopia. The agent is then activated by light of a specific wavelength in the presence of oxygen and causes local damage to the neovascular endothelium followed by vessel occlusion. It is administered intravenously before irradiation of the lesion with light from a compatible laser.
References in periodicals archive ?
and photosensitizers such as rose bengal and benzoporphyrin derivatives, which produce [sup.
Second-generation photosensitizers include 5-aminolevulinic acid (ALA), benzoporphyrin derivative (BPD), lutetium texaphyrin, temoporfin (mTHPC), tinethyletiopurpurin(SnET2), and talaporfin sodium (LS11).
Four photosensitizing drugs, Photofring, Texas Red, a benzoporphyrin derivative monoacid (BPD), and lutetium texaphyrin (LuTex) were tested to see if they were substrates of the MDR-1 multidrug resistor pump, or if they could be used in PDT.
Quadra Logic is today testing an even stronger free radical-releasing drug called benzoporphyrin derivative, or BPD, which is also activated by light.
QLT's second-generation product, Benzoporphyrin derivative (BPD-MA) is undergoing clinical trials for the treatment of age-related macular degeneration, the leading cause of blindness in the elderly.
Second generation include 5-aminolevulinic acid (ALA), benzoporphyrin derivatives (BPD), temoporfin (mTHPC) and talaporphin sodium (LS11).
In a multi-center Phase I/II clinical trial, co-sponsored by QLT and CIBA Vision, researchers presented preliminary ocular safety and proof-of-principle data suggesting that the light-activated drug, Benzoporphyrin derivative (BPD), can selectively close abnormal blood vessels in the eye that are associated with the severe or "wet" form of Age-related Macular Degeneration (AMD) without causing vision loss associated with currently available treatments.
The Company has several drugs under development, including clinical trials for Benzoporphyrin derivative (BPD), a second-generation photosensitizer.
Second, global development activities with CIBA Vision will be focused on completing clinical trials and securing marketing approvals for BPD (the company's second-generation drug, benzoporphyrin derivative, now in Phase II clinical trials) for the treatment of age-related macular degeneration.
The Company has several drugs under development, including the approved product PHOTOFRIN(R) and clinical trials for Benzoporphyrin derivative, a second-generation photosensitizer.
The company has several drugs under development, including Benzoporphyrin derivative, a second-generation photosensitizer, currently in clinical trials.
BOSTON, MA--(BUSINESS WIRE)--MAY 2, 1995--QUADRA LOGIC(TSE: QLT NASDAQ: QLTIF) Researchers at the Massachusetts Eye and Ear Infirmary and Harvard Medical School have commenced a Phase I safety and proof- of-concept clinical study involving the use of the light-activated drug, Benzoporphyrin derivative (BPD), as a potential treatment for Age-related Macular Degeneration.